市场调查报告书
商品编码
1370641
粒子治疗市场-按类型(质子、重离子)、副产品(同步加速器、迴旋加速器)、按服务、按系统(多室系统、单室系统)、按癌症类型(小儿癌、肺癌、膀胱癌、乳腺癌症)及预测,2023-2032Particle Therapy Market-By Type (Proton, Heavy Ion), By Product (Synchrotrons, Cyclotrons), By Services, By System (Multi-Room Systems, Single-Room Systems), By Cancer Type (Pediatric Cancer, Lung Cancer, Bladder, Breast Cancer) & Forecast, 2023-2032 |
2023 年至 2032 年间,全球粒子治疗市场的复合年增长率将超过 8.7%。由于领先的医院和医疗机构越来越多地采用尖端粒子治疗设备,预计该市场将蓬勃发展。例如,2023 年 9 月,粒子加速器技术的全球领导者和癌症治疗质子治疗解决方案的领先供应商 ION Beam Applications SA (IBA) 与 Medtechnica Ltd 正式签署了最终协议。该协议为在以色列特拉维夫的Sourasky 医疗中心(也称为Ichilov 医院)安装了两台最先进的Proteus (R)ONE 紧凑型质子治疗系统。
这些医院正在选择顶级製造商的优质设备,这反过来又推动了粒子治疗市场的成长。粒子疗法精确且有效的治疗能力是这一趋势的关键因素,因为医疗保健提供者力求为患者提供最佳的护理。
整个粒子治疗市场根据产品、癌症类型和地区进行分类。
迴旋加速器领域将在 2023 年至 2032 年间经历重大发展。迴旋加速器透过将这些粒子加速到精确的能量以实现有效的治疗,从而在癌症治疗中发挥关键作用。随着医学界越来越认识到粒子治疗的精确度和益处,对迴旋加速器的需求不断增加,支撑了粒子治疗的市场前景。由于上述原因,对迴旋加速器的需求正在快速成长,迴旋加速器是生产质子和重离子治疗所需粒子的重要组成部分。
2023年至2032年,儿科癌症领域将出现显着的复合年增长率。粒子疗法,包括质子和重离子疗法,因其精确性和副作用减少而受到关注,使其成为年轻癌症患者的理想选择。随着人们对粒子疗法在治疗儿童癌症方面的优势的认识不断增强,这一专业领域的粒子疗法市场需求正在增加。
亚太地区粒子治疗市场将于 2023 年至 2032 年呈现可观的复合年增长率。人口增长、癌症发病率增加以及对粒子治疗益处的更多认识等因素正在推动这一需求。亚洲国家正在扩大其医疗基础设施,包括质子和重离子治疗设施,这显示亚太地区的市场成长轨迹显着。例如,2023 年 10 月,日立有限公司和日立亚洲有限公司在一份联合声明中披露,已成功向新加坡国家癌症中心(「NCCS」)交付质子治疗系统。这项成就标誌着日立首个质子治疗系统在东南亚用于病患治疗的开创性时刻。
Global Particle Therapy Market will witness over 8.7% CAGR between 2023 and 2032. The market is expected to flourish due to the increasing adoption of cutting-edge particle therapy equipment by leading hospitals and health facilities. For instance, in September 2023, ION Beam Applications S.A. (IBA), a global frontrunner in particle accelerator technology and the foremost provider of proton therapy solutions for cancer treatment, officially inked the conclusive agreement with Medtechnica Ltd. This agreement paves the way for the installation of two state-of-the-art Proteus®ONE compact proton therapy systems at the Sourasky Medical Center, also known as Ichilov Hospital, in Tel Aviv, Israel.
These hospitals are choosing high-quality equipment from top manufacturers, which, in turn, fuels the particle therapy market growth. The precise and effective treatment capabilities of particle therapy are a key factor in this trend, as healthcare providers seek to offer the best possible care to their patients.
The overall Particle Therapy Market is classified based on product, cancer type, and region.
Cyclotrons segment will undergo significant development from 2023 to 2032. Cyclotrons play a pivotal role in cancer treatment by accelerating these particles to precise energies for effective therapies. As the medical community increasingly recognizes the precision and benefits of particle therapy, the demand for cyclotrons is on the rise, supporting the particle therapy market outlook. The demand for cyclotrons, which are integral in producing the necessary particles for proton and heavy ion therapy, is registering high growth due to the above-stated reasons.
The pediatric cancer segment will register a notable CAGR from 2023 to 2032. Particle therapy, including proton and heavy ion therapy, is gaining prominence for its precision and reduced side effects, making it an ideal choice for young cancer patients. As awareness grows about the advantages of particle therapy in treating pediatric cancers, the particle therapy market demand in this specialized field is on the rise.
Asia Pacific particle therapy market will showcase an appreciable CAGR from 2023 to 2032. Factors such as a growing population, increasing cancer incidence, and a greater awareness of the benefits of particle therapy are driving this demand. Asian countries are expanding their healthcare infrastructure to include proton and heavy ion therapy facilities, indicating a significant market growth trajectory in the Asia Pacific. For instance, in October 2023, in a joint statement, Hitachi, Ltd. and Hitachi Asia Ltd. disclosed the successful delivery of a proton therapy system to the National Cancer Centre Singapore ("NCCS"). This achievement marks a groundbreaking moment as Hitachi's inaugural proton therapy system to be operational for patient treatment in Southeast Asia.